At the time, Opthea said it would consider the impact on the phase 3 Shore trial—which has been assessing sozinibercept in combination with Novartis’ Lucentis and was due to read out this year.

Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.

It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...

Wer sehr schlank ist oder in den Oberschenkel spritzt, sollte immer eine Hautfalte bilden, um eine Injektion in den Muskel vermeiden. 5. Einstichstelle und Nadel wechseln: Spritzen Sie Insulin nicht ...